Vontobel Holding’s Anavex Life Sciences AVXL Stock Holding History

Vontobel Holding’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-60,000	Closed	-$1.04M	–	1059
2021 Q4	$1.04M	Hold	60,000	–	–	0.01%	621
2021 Q3	$1.08M	Hold	60,000	–	–	0.01%	599
2021 Q2	$1.37M	Hold	60,000	–	–	0.01%	520
2021 Q1	$897K	Hold	60,000	–	–	0.01%	554
2020 Q4	$324K	Buy	+60,000	New	+$316K	﹤0.01%	782

Other funds holding AVXL

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Vontobel Holding's AVXL Position: Q1 2022 in Review

Vontobel Holding sold out of Anavex Life Sciences (AVXL) in Q1 2022, closing a stake of 60,000 shares — an estimated $1.04M sold.

Vontobel Holding first reported a position in AVXL in Q4 2020 and held it in 5 quarters. The position peaked at $1.37M in Q2 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q1 2022.

Vontobel Holding reported no remaining Anavex Life Sciences position as of Q1 2022 after selling out during the quarter.
Vontobel Holding sold 60,000 Anavex Life Sciences shares in Q1 2022, an estimated $1.04M.
Vontobel Holding first reported a position in Anavex Life Sciences in Q4 2020 and held it in 5 quarters.
Vontobel Holding's Anavex Life Sciences position peaked at $1.37M in Q2 2021.
139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2022.

Based on Vontobel Holding's 13F filing for Q1 2022, filed 13 May 2022.